Previous studies in prostate cancer have shown that abiraterone targets not only steroidogenesis but also directly antagonises AR activity.30 As 80% of ER+ breast cancer patients also express AR,12,13 we explored the notion that blocking AR signalling with abiraterone may provide benefit in ER+ breast cancer. This evidence concerns the gene ESR1 and breast carcinoma.